Christina Yap

7.0k total citations · 2 hit papers
113 papers, 2.4k citations indexed

About

Christina Yap is a scholar working on Statistics and Probability, Economics and Econometrics and Oncology. According to data from OpenAlex, Christina Yap has authored 113 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Statistics and Probability, 30 papers in Economics and Econometrics and 19 papers in Oncology. Recurrent topics in Christina Yap's work include Statistical Methods in Clinical Trials (34 papers), Health Systems, Economic Evaluations, Quality of Life (30 papers) and Meta-analysis and systematic reviews (15 papers). Christina Yap is often cited by papers focused on Statistical Methods in Clinical Trials (34 papers), Health Systems, Economic Evaluations, Quality of Life (30 papers) and Meta-analysis and systematic reviews (15 papers). Christina Yap collaborates with scholars based in United Kingdom, United States and Malaysia. Christina Yap's co-authors include Joshua Z. Goldenberg, Lyubov Lytvyn, Calvin Ka-Fung Lo, Jennifer Beardsley, Dominik Mertz, Bradley C. Johnston, James Wason, Christopher J. Weir, Adrian Mander and Thomas Jaki and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Christina Yap

107 papers receiving 2.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adaptive designs in clinical trials: why use them, and how to run and report them

2018 415 citations Philip Pallmann, Alun Bedding et al. BMC Medicine profile →
Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children

2017 385 citations Christina Yap et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christina Yap United Kingdom	23	435	399	397	340	280	113	2.4k
Andrea R. Horvath Australia	30	461 1.1×	469 1.2×	153 0.4×	522 1.5×	282 1.0×	124	3.8k
Song Zhang United States	31	283 0.7×	456 1.1×	153 0.4×	102 0.3×	115 0.4×	120	2.5k
Kiyoshi Ichihara Japan	33	406 0.9×	722 1.8×	194 0.5×	162 0.5×	161 0.6×	189	3.5k
Aurélien Latouche France	24	129 0.3×	273 0.7×	444 1.1×	178 0.5×	75 0.3×	62	2.2k
John Hornberger United States	21	143 0.3×	331 0.8×	95 0.2×	211 0.6×	115 0.4×	42	2.8k
Cornelis Boersma Netherlands	17	142 0.3×	416 1.0×	230 0.6×	108 0.3×	73 0.3×	78	2.5k
Sylvain Mathieu France	26	295 0.7×	337 0.8×	75 0.2×	272 0.8×	61 0.2×	92	2.4k
Sally Hunsberger United States	33	699 1.6×	526 1.3×	764 1.9×	761 2.2×	295 1.1×	98	4.4k
Lang Chen United States	40	386 0.9×	547 1.4×	57 0.1×	280 0.8×	254 0.9×	113	4.6k
Peter K. K. Wong Australia	21	293 0.7×	287 0.7×	65 0.2×	177 0.5×	114 0.4×	64	3.3k

Countries citing papers authored by Christina Yap

Since Specialization

Citations

This map shows the geographic impact of Christina Yap's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christina Yap with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christina Yap more than expected).

Fields of papers citing papers by Christina Yap

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christina Yap. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christina Yap. The network helps show where Christina Yap may publish in the future.

Co-authorship network of co-authors of Christina Yap

This figure shows the co-authorship network connecting the top 25 collaborators of Christina Yap. A scholar is included among the top collaborators of Christina Yap based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christina Yap. Christina Yap is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wilson, I. H., Steven A. Julious, Christina Yap, Susan Todd, & Munyaradzi Dimairo. (2025). Response adaptive randomisation in clinical trials: Current practice, gaps and future directions. Statistical Methods in Medical Research. 34(9). 1851–1874. 1 indexed citations

Zachariou, Athanasios, Sudhir Venkatesan, Xiaolin Hu, et al.. (2025). 85P: Phase I results from the phase I/II POTENT trial of tepotinib and pembrolizumab in non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 20(3). S62–S63.

Kong, Anthony, Amanda Kirkham, Joshua Savage, et al.. (2024). Results and lessons learnt from the WISTERIA phase I trial combining AZD1775 with cisplatin pre- or post-operatively in head and neck cancer. PubMed. 2(1). 6–6. 3 indexed citations

Mander, Adrian, et al.. (2024). Handling Incomplete or Late-Onset Toxicities in Early-Phase Dose-Finding Clinical Trials: Current Practice and Future Prospects. JCO Precision Oncology. 8(8). e2300441–e2300441. 3 indexed citations

Lee, Shing M., et al.. (2024). U-PRO-CRM: designing patient-centred dose-finding trials with patient-reported outcomes. ESMO Open. 9(7). 103626–103626. 4 indexed citations

Bono, Johann S. de, Simon Lord, Christina Yap, et al.. (2023). 687P A CRUK phase I/IIA, first in human dose-escalation and expansion trial of HMBD-001 (an anti-HER3 antibody) in patients with advanced HER3 positive solid tumours. Annals of Oncology. 34. S479–S480. 1 indexed citations

Jahan, Nowrozy Kamar, et al.. (2023). Impact of Climate Change on Women’s Mental Health: A Narrative Review. OALib. 10(12). 1–15.

Mergental, Hynek, Richard W. Laing, Amanda Kirkham, et al.. (2023). Discarded livers tested by normothermic machine perfusion in the VITTAL trial: Secondary end points and 5-year outcomes. Liver Transplantation. 30(1). 30–45. 16 indexed citations

Lai‐Kwon, Julia, Anna Minchom, Olalekan Lee Aiyegbusi, et al.. (2022). Using Patient-Reported Outcomes in Dose-Finding Oncology Trials: Surveys of Key Stakeholders and the National Cancer Research Institute Consumer Forum. The Oncologist. 27(9). 768–777. 6 indexed citations

10.

Grayling, Michael J., Adrian Mander, Nurulamin M Noor, et al.. (2022). Subgroup analyses in randomized controlled trials frequently categorized continuous subgroup information. Journal of Clinical Epidemiology. 150. 72–79. 8 indexed citations

11.

Homer, Victoria, Christina Yap, Simon Bond, et al.. (2022). Early phase clinical trials extension to guidelines for the content of statistical analysis plans. BMJ. 376. e068177–e068177. 17 indexed citations

12.

Wason, James, Munyaradzi Dimairo, Katie Biggs, et al.. (2022). Practical guidance for planning resources required to support publicly-funded adaptive clinical trials. BMC Medicine. 20(1). 254–254. 6 indexed citations

13.

Kong, Anthony, James Good, Amanda Kirkham, et al.. (2020). Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: the WISTERIA trial protocol. BMJ Open. 10(3). e033009–e033009. 26 indexed citations

14.

Bono, Petri, Panu Jaakkola, Shishir Shetty, et al.. (2020). 1024MO A phase I/II MATINS trial: Part 1 pharmacokinetic, safety and efficacy results of Clever-1 blockade in advanced cancer. Annals of Oncology. 31. S706–S707. 1 indexed citations

15.

Pallmann, Philip, Fang Wan, Adrian Mander, et al.. (2019). Designing and evaluating dose-escalation studies made easy: The MoDEsT web app. Clinical Trials. 17(2). 147–156. 7 indexed citations

16.

Pallmann, Philip, Alun Bedding, Babak Choodari‐Oskooei, et al.. (2018). Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Medicine. 16(1). 29–29. 415 indexed citations breakdown →

17.

Yap, Christina, Lucinda Billingham, Ying Kuen Cheung, Charles Craddock, & John O’Quigley. (2017). Dose Transition Pathways: The Missing Link Between Complex Dose-Finding Designs and Simple Decision-Making. Clinical Cancer Research. 23(24). 7440–7447. 21 indexed citations

18.

Laing, Richard W., Hynek Mergental, Christina Yap, et al.. (2017). Viability testing and transplantation of marginal livers (VITTAL) using normothermic machine perfusion: study protocol for an open-label, non-randomised, prospective, single-arm trial. BMJ Open. 7(11). e017733–e017733. 90 indexed citations

19.

Fox, Stephen B., Christina Yap, Aimee E. Houlton, et al.. (2016). RUXOLITINIB COMPARED WITH BEST AVAILABLE THERAPY FOR ESSENTIAL THROMBOCYTHAEMIA PATIENTS RESISTANT OR INTOLERANT TO HYDROXYCARBAMIDE IN MAJIC - AN INVESTIGATOR LEAD RANDOMIZED TRIAL. Haematologica. 101. 97–97. 1 indexed citations

20.

Shenton, B.K., et al.. (2002). Use of real-time PCR to measure Epstein–Barr virus genomes in whole blood. Journal of Immunological Methods. 270(2). 259–267. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact